This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Journals
    Journal
    01/02/19

    The New Heart Failure Association Definition of Advanced Heart Failure

    The clinical course of heart failure is characterised by progressive worsening of cardiac function and symptoms. Patients progress to a condition where traditional treatment is no longer effective and advanced therapies...

    • Source: Cardiac Failure Review
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    08/02/22

    Breakthrough results for Jardiance confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction. Eli Lilly + Boehringer.

    The EMPEROR-Preserved phase III trial met its primary endpoint, establishing Jardiance (empagliflozin) from Eli Lilly and Boehringer, as the first and only therapy to significantly reduce the risk of the composite of cardiovascular death or hospitalization for heart failure in adults, with or without diabetes, who live with heart failure with preserved ejection fraction (HFpEF).

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    05/05/22

    Farxiga met primary endpoint in DELIVER phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction.

    High-level results from the DELIVER Phase III trial showed AstraZeneca’s Farxiga (dapagliflozin) reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular (CV) death or worsening heart failure (HF).

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    08/02/22

    EMPEROR-Preserved trial demonstrates Jardiance is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction.- Eli Lilly + Boehringer.

    Full results from the landmark EMPEROR-Preserved phase III trial demonstrated that Jardiance (empagliflozin) showed an impressive 21% relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure in adults with heart failure with preserved ejection fraction (HFpEF) compared with placebo.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    09/04/22

    Jardiance now approved by PMDA in Japan for use in patients with chronic heart failure with preserved ejection fraction (HFpEF)- Nippon Boehringer + Eli Lilly.

    Nippon Boehringer Ingelheim’s SGLT2 inhibitor Jardiance (empagliflozin) has obtained a label update from PMDA in Japan allowing its use in patients with chronic heart failure with preserved ejection fraction (HFpEF) in addition to those with heart failure with reduced ejection fraction (HFrEF).

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    03/02/25

    Results from Phase III SUMMIT study show tirzepatide significantly reduced the risk of worsening heart failure events in patients with heart failure and obesity - Eli Lilly

    Eli Lilly and Company  announced detailed results from the SUMMIT Phase III trial showing tirzepatide significantly reduced the risk of worsening heart failure events in adults with heart failure with preserved ejection fraction (HFpEF) and obesity.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    05/08/24

    Finerenone meets primary endpoint in phase III FINEARTS-HF cardiovascular outcomes study in patients with heart failure with mildly reduced or preserved ejection fraction

    The Phase III study FINEARTS-HF, evaluating the efficacy and safety of finerenone versus placebo when added to usual therapy in patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of greater than or equal to 40%, has met its primary endpoint

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    07/02/23

    Forxiga approved in the EU for the treatment of symptomatic chronic heart failure

    Forxiga (dapagliflozin) has been approved in the European Union to extend the indication for heart failure (HF) with reduced ejection fraction (HFrEF) to cover patients across the full spectrum of left ventricular ejection fraction (LVEF), including HF with mildly reduced and preserved ejection fraction (HFmrEF, HFpEF)

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    28/08/23

    Additional studies with finerenone across a wide range of heart failure patients initiated.- Bayer

    Bayer will support the initiation of three additional studies to extend its heart failure (HF) program with finerenone (MOONRAKER program).

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    21/08/19

    Phase III DAPA-HF trial of Farxigapositive for treatment of heart failure

    AstraZeneca announced positive results from the landmark Phase III DAPA-HF trial which showed that Farxiga (dapagliflozin) met the primary composite...

    See more